U.S.-based Huya Bioscience Signs Drug Development Pact With China's Guangzhou Institutes Of Biomedicine
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Huya Bioscience International has signed a partnership agreement with the Guangzhou Institutes of Biomedicine and Health on the joint development of innovative compounds that could provide a bridge between GIBH scientists and the global market, according to Huya's senior leadership
You may also be interested in...
California's Huya And China Medical City Create Alliance To Develop Chinese Pharmaceutical Projects
SHANGHAI - Huya Bioscience International has entered into a strategic alliance to help accelerate the development of innovative R&D projects originating in China Medical City, in the Taizhou National Medical Hi-tech Development Zone
California's Huya And China Medical City Create Alliance To Develop Chinese Pharmaceutical Projects
SHANGHAI - Huya Bioscience International has entered into a strategic alliance to help accelerate the development of innovative R&D projects originating in China Medical City, in the Taizhou National Medical Hi-tech Development Zone
Huya Bioscience Enters Into U.S., European Deals That Could Help Channel Innovative Chinese Drugs Into Pipelines Of International Pharma Outfits
BEIJING - In transactions that could help channel innovative Chinese drugs into the pipelines of global pharmaceutical outfits, Huya Bioscience International has signed separate deals with the U.S.-headquartered Abbott Laboratories and the Belgian-based Solvay Pharmaceuticals to identify lead compounds for potential licensing agreements